期刊文献+

药源性肾损害的临床新视点 被引量:3

下载PDF
导出
摘要 肾脏在物质排泄、体液控制、电解质平衡及保持机体内环境稳定等方面均起着重要作用,但也是体内特别易受到药物毒性影响的器官之一。在社区及医院获得性急性肾衰竭患者中约20%为药源性,老年患者中药源性肾损害发生率更是高达66%。
出处 《中国医院用药评价与分析》 2016年第3期431-432,共2页 Evaluation and Analysis of Drug-use in Hospitals of China
  • 相关文献

参考文献17

  • 1曾诚.药源性肾损害[J].中国医院药学杂志,2013,33(4):319-321. 被引量:13
  • 2Kiyomi K,Satoshi M, Takuma H, et al. Case of acute kidney injury related to intravenous zoledronic acid in a patient with muhiple myeloma [ J ]. Nihon Jinzo Gakkai Shi,2009,51 ( 5 ) :557-562. 被引量:1
  • 3Diel I J, Weide R, Koppler H, et al. Risk of renal impairment after treatment with ibandronate versus zoledronic acid: a retrospective medical records review [ J ]. Support Care Cancer,2009,17 ( 6 ) :719- 725. 被引量:1
  • 4FDA. FDA Drug Safety Communication: New contraindication and updated warning on kidney impairment for Reclast (zoledronic acid [ EB/OL ]. ( 2011-09-01 ) [ 2011-10-23 ]. http ://www. Fda. gov/ Drug/DrugSafety/ucm270199. htm. 被引量:1
  • 5Vallakati A, Chandra PA, Hollander G, et al. Direct renin inhibitor induced renal failure[ J]. Am J Ther,2014,21 (2) :53-55. 被引量:1
  • 6Sen S, Sablrh S, Ozyigit T, et al. Aliskiren: review of efficacy and safety data with focus on past and recent clinical trials [ J ]. Ther Adv Chronic Bis ,2013,4(5 ) :232-241. 被引量:1
  • 7方向,胡世莲,吴蕾,陈尹,徐维平,唐杨琛,沈干.阿利吉仑在联合降压治疗中安全性的系统评价[J].中华高血压杂志,2014,22(7):639-645. 被引量:2
  • 8Perner A, Haase N, Guttormsen AB, et al. Hydroxyethyl starch 130/0.4 versus Ringer's acetate in severe sepsis [ J]. N Engl J Med, 2012,367(2) :124-134. 被引量:1
  • 9Rioux JP, Lessard M, De Bortoli B, et al. Pentastarch 10% (250 kDa/0.45 ) is an independent risk factor of acute kidney injury following cardiac surgery[ J]. Critical care medicine, 2009,37 ( 4 ) : 1293-1298. 被引量:1
  • 10FDA. Hydroxyethyl starch solutions: FDA safety communication- boxed warning on increased mortality and severe renal injury and risk of bleeding [ EB/OL]. [ 2013-06-24 ]. http://www, fda. gov/ Safety/MedWatch/Safetylnformation/Safety Alertsfor Human Medical Products/ucm358349. htm. 被引量:1

二级参考文献40

  • 1李鹤英,张虹,曹维莉,郭齐,吴春玲.羟乙基淀粉导致急性肾功能衰竭13例分析[J].临床荟萃,2004,19(16):953-953. 被引量:2
  • 2姚桂莲,刘健,王淑翠.羟乙基淀粉致过敏性休克死亡[J].药物不良反应杂志,2006,8(3):213-214. 被引量:7
  • 3FDA. Hydroxyethyl starch solutions:FDA safety communi- cation-boxed warning on increased mortality and severe renal injury and risk of bleeding [ EB/OL]. [2013 -06 - 24]. http ://www. fda. gov/Safety/MedWatch/Safety Information/Safety Alertsfor Human Medical Products/ ucm358349, htm. 被引量:1
  • 4MYBURGH J A, FINFER S, BELLOMO R, et al. Hydrox- yethyl starch or saline for fluid resuscitation in intensive care[J]. N Engl J Med,2012,367(20):1901-1911. 被引量:1
  • 5ZARYCHANSKI R, ABOU-SETTA A M ,TURGEON A F ,et al. Association of hydroxyethyl starch administration with mortality and acute kidney injury in critically ill patients requiring volume resuscitation: a systematic review and meta-analysis[ J]. JAMA ,2013,309 (7) :678-688. 被引量:1
  • 6梁芝萍,邢诺.中分子羟乙基淀粉130/0.4致过敏性休克1例[J].华北国防医药,2009,21(4):32. 被引量:1
  • 7Pedelty L, Goreliek PB. Management of hypertension and cere- brovaseular disease in the elderly[J]. Am J Med, 2008,121 (8 Sup- pI) :S23-31. 被引量:1
  • 8HareI Z, Gilbert C, Wald R, et al. The effect of combination treatment with aliskiren and blockers of the renin-angiotensin sys- tem on hyperkalaemia and acute kidney injury: systematic review and meta-analysis[J]. BMJ ,2012,344 :e42. 被引量:1
  • 9Gilbert CJ, Gomes T, Mamdani MM, et al. No increase in ad- verse events during aliskiren use among ontario patients receiving angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers[J]. Can J Cardiol.2013.29(5) :586-591. 被引量:1
  • 10Riecioni G. Aliskiren in the treatment of hypertension and organ damage[J]. Cardiovasc Ther, 2011,29 ( 1 ) : 77-87. 被引量:1

共引文献18

同被引文献26

引证文献3

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部